Iron therapy and severe arrhythmias in HFrEF: rationale, study design, and baseline results of the RESAFE‐HF trial

AIMS: The Iron Intravenous Therapy in Reducing the burden of Severe Arrhythmias in HFrEF (RESAFE‐HF) registry study aims to provide real‐word evidence on the impact of intravenous ferric carboxymaltose (FCM) on the arrhythmic burden of patients with heart failure with reduced ejection fraction (HFrE...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakogiannis, Constantinos, Mouselimis, Dimitrios, Tsarouchas, Anastasios, Papadopoulos, Christodoulos E., Theofillogiannakos, Efstratios K., Lechat, Elmira, Antoniadis, Antonios P., Pagourelias, Efstathios D., Kelemanis, Ioannis, Tzikas, Stergios, Fragakis, Nikolaos, Efthimiadis, Georgios K., Karamitsos, Theodoros D., Doumas, Michael, Vassilikos, Vassilios P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053179/
https://www.ncbi.nlm.nih.gov/pubmed/36647691
http://dx.doi.org/10.1002/ehf2.14276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053179/
https://www.ncbi.nlm.nih.gov/pubmed/36647691
http://dx.doi.org/10.1002/ehf2.14276

Ejemplares similares